Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab in Subjects With Giant Cell Arteritis

NCT01791153 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01791153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01791153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab in Subjects With Giant Cell Arteritis
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
July 22, 2013
Completion date
June 4, 2018
Enrollment
251 (actual)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

giant cell arteritis